170 filings
Page 2 of 9
8-K
0lyw7n5
12 Apr 22
Other Events
4:07pm
8-K
04no5nehun
12 Apr 22
Regulation FD Disclosure
9:00am
8-K
kb81wlie6xehb
28 Feb 22
Humanigen Reports Year-End 2021 Financial Results
4:01pm
8-K
6o9kzmehgc8
5 Jan 22
Other Events
6:04am
8-K
m73zlcgx
2 Dec 21
Other Events
8:00am
8-K
913gyzg8sh biua2i
26 Nov 21
Departure of Directors or Certain Officers
5:00pm
8-K
e31g 8scksj0szbot
12 Nov 21
Results of Operations and Financial Condition
4:01pm
8-K
hx1r7k s0
9 Nov 21
Regulation FD Disclosure
8:00am
8-K
riq7snid05ucr665my
20 Oct 21
Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors
9:13am
8-K
clda76xb
5 Oct 21
Departure of Directors or Certain Officers
4:05pm
8-K
ruxo2iam9 7db
14 Sep 21
Regulation FD Disclosure
5:00pm
8-K
hq1r0597w v6gcmcc
10 Sep 21
Other Events
6:01am
8-K
fi7sj05pre vfx5a
12 Aug 21
Humanigen Reports Second Quarter 2021 Financial Results
4:01pm
8-K
91kzarfnh
4 Aug 21
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
6:04am
8-K
4f8bnb83 zu
14 Jul 21
Regulation FD Disclosure
11:58am
8-K
sys8y
21 Jun 21
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
4q35n1joiqjgojwx wj
17 Jun 21
Humanigen 2021 Annual Stockholder Meeting June 17
6:30am
8-K
tl9a7t mhfzdy7
28 May 21
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
5:00pm
8-K
w1a79ulyhcs3s f7yti
13 May 21
Humanigen Reports First Quarter 2021 Financial Results
4:06pm
8-K
f0p5fvv4i4rd8b7016o
20 Apr 21
Humanigen Reports Positive Data with Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
5:28pm